Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches

Area of Science:

• Virology and Immunology
• Vaccine Development

Background:

• Respiratory syncytial virus (RSV) is a major global health concern, particularly for pediatric populations.
• The RSV fusion (F) and attachment (G) glycoproteins are critical targets for neutralizing antibodies, but their variability presents vaccine development challenges.
• The metastable pre-F protein, essential for viral entry, has been identified as a promising vaccine candidate.

Purpose of the Study:

• To review RSV pathogenesis and host immune responses.
• To summarize recent advancements in RSV vaccine development and vaccination strategies.
• To highlight the potential of pre-F vaccines for protecting vulnerable populations, including infants.

Main Methods:

• Analysis of RSV structure, focusing on the fusion (F) protein's antigenic sites.
• Review of studies investigating pre-F protein immunization in animal models.
• Evaluation of strategies for protecting neonates, including passive immunity through maternal vaccination.

Main Results:

• Novel antigenic sites, including site ø, were identified on stabilized pre-F protein, demonstrating superior neutralizing activity.
• Pre-F immunization in animal models successfully induced high neutralizing antibody responses, supporting its vaccine potential.
• Maternal vaccination during the third trimester is proposed as an effective strategy to confer passive immunity to newborns.

Conclusions:

• The pre-F protein represents a significant advancement in RSV vaccine development due to its immunogenicity and the identification of potent antigenic sites.
• Vaccination strategies targeting pregnant women offer a viable approach to protect vulnerable infants from severe RSV infection.
• Continued research into RSV pathogenesis and vaccine efficacy is crucial for global public health.